16566-20-4Relevant academic research and scientific papers
Quinoxalines useful as cytoprotective agents
-
Page/Page column 34, (2020/08/16)
Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
Preparation method of benzopyridazine derivative
-
, (2018/03/25)
The invention discloses a preparation method of a benzopyridazine derivative 5-bromobenzopyridazine; 1,2-diamino-3-nitrobenzene as a starting raw material is subjected to cyclization, reduction and Sandmeryer reaction to obtain the target product; the compound is an important pharmaceutical intermediate.
Synthetic method of quinoxaline-5-sulfonyl chloride
-
, (2018/05/01)
The invention discloses a synthetic method of quinoxaline-5-sulfonyl chloride. The synthetic method is characterized by comprising the following steps that S1, a condensation reaction is carried out on 1,2-diamino-3-nitrobenzene with glyoxal for obtaining 5-nitroquinoxaline; S2, the 5-nitroquinoxaline reacts with a reducing agent for generating 5-aminoquinoxaline; and S3, diazotization reaction and Sandermeyer reaction are carried out on the 5-aminoquinoxaline for obtaining the quinoxaline-5-sulfonyl chloride. According to the process, a novel Sandermeyer reaction strategy is adopted for introducing sulfonyl chloride groups, the yield is greater than 70%, and the characteristics of novel process route, relatively mild reaction conditions and the like are achieved.
ANTI-HCMV COMPOSITIONS AND METHODS
-
, (2016/06/06)
This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.
6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists
Sun, Wei,Kim, Hyo-Shin,Lee, Sunho,Jung, Aeran,Kim, Sung-Eun,Ann, Jihyae,Yoon, Suyoung,Choi, Sun,Lee, Jin Hee,Blumberg, Peter M.,Frank-Foltyn, Robert,Bahrenberg, Gregor,Schiene, Klaus,Stockhausen, Hannelore,Christoph, Thomas,Frormann, Sven,Lee, Jeewoo
, p. 803 - 806 (2015/02/19)
A series of N-[{2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)-pyridin-3-yl}methyl] N′-(6,6-fused heterocyclic) ureas have been investigated as hTRPV1 antagonists. Among them, compound 15 showed highly potent TRPV1 antagonism to capsaicin, with Ki(ant) = 0.2 nM, as well as antagonism to other activators, and it was efficacious in a pain model. A docking study of 15 with our hTRPV1 homology model indicates that there is crucial hydrogen bonding between the ring nitrogen and the receptor, contributing to its potency.
PERHYDROQUINOXALINE DERIVATIVES USEFUL AS ANALGESICS
-
, (2014/12/12)
The present invention relates to perhydroquinoxaline compounds according to the general formula (1), their use as a medicament, in particular as analgesic, antipruritic and antiinflammatory agents, and their preparation.
Studies toward the discovery of the next generation of antidepressants. Part 6: Dual 5-HT1A receptor and serotonin transporter affinity within a class of arylpiperazinyl-cyclohexyl indole derivatives
Zhou, Dahui,Zhou, Ping,Evrard, Deborah A.,Meagher, Kristin,Webb, Michael,Harrison, Boyd L.,Huryn, Donna M.,Golembieski, Jeannette,Hornby, Geoffrey A.,Schechter, Lee E.,Smith, Deborah L.,Andree, Terrance H.,Mewshaw, Richard E.
, p. 6707 - 6723 (2008/12/21)
Based on the previously reported discovery lead, 3-(cis-4-(4-(1H-indol-4-yl)piperazin-1-yl)cyclohexyl)-5-fluoro-1H-indole (2), a series of related arylpiperazin-4-yl-cyclohexyl indole analogs were synthesized then evaluated as 5-HT transporter inhibitors
Furazan ring opening upon treatment of benzofurazan with ethanolamine to yield quinoxalines
Samsonov
experimental part, p. 2510 - 2512 (2009/02/05)
Heating of benzofurazans with ethanolamine in the presence of catalytic amount of p-toluenesulfonic acid leads to quinoxalines.
PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION
-
Page/Page column 50, (2010/10/20)
There is provided compounds of formula (I), wherein R1, R2, Ra and Rb have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.
Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain; Structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaliue, and cinnoline moieties
Gomtsyan, Arthur,Bayburt, Erol K.,Schmidt, Robert G.,Guo, Zhu Zheng,Perner, Richard J.,Didomenico, Stanley,Koenig, John R.,Turner, Sean,Jinkerson, Tammie,Drizin, Irene,Hannick, Steven M.,Macri, Bryan S.,McDonald, Heath A.,Honore, Prisca,Wismer, Carol T.,Marsh, Kennan C.,Wetter, Jill,Stewart, Kent D.,Oie, Tetsuro,Jarvis, Michael F.,Surowy, Carol S.,Faltynek, Connie R.,Lee, Chih-Hung
, p. 744 - 752 (2007/10/03)
Novel transient receptor potential vanilloid 1 (TRPV1) receptor antagonists with various bicyclic heteroaromatic pharmacophores were synthesized, and their in vitro activity in blocking capsaicin activation of TRPV1 was assessed. On the basis of the contribution of these pharmacophores to the in vitro potency, they were ranked in the order of 5-isoquinoline > 8-quinoline = 8-quinazoline > 8-isoquinoline ≥ cinnoline ≈ phthalazine ≈ quinoxaline ≈ 5-quinoline. The 5-isoquinoline-containing compound 14a (hTRPV1 IC50 = 4 nM) exhibited 46% oral bioavailability and in vivo activity in animal models of visceral and inflammatory pain. Pharmacokinetic and pharmacological properties of 14a are substantial improvements over the profile of the high-throughput screening hit 1 (hTRPV1 IC50 = 22 nM), which was not efficacious in animal pain models and was not orally bioavailable.
